Omvoh Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in inflammatory bowel disease research, increasing diagnosis of ulcerative colitis, expansion of biologic infusion infrastructure, improved clinical trial outcomes for il-23 inhibitors, rising specialist gastroenterology care.

The growth in the forecast period can be attributed to growing adoption of targeted immunology therapies, expansion of biologic maintenance treatments, increasing focus on steroid-sparing regimens, rising investments in inflammatory disease drug development, continued innovation in monoclonal antibody platforms. Major trends in the forecast period include increasing adoption of il-23 targeted biologic therapies, rising focus on precision treatment for ibd, expansion of combination induction and maintenance regimens, growing use of injectable monoclonal antibodies, enhanced monitoring of treatment response.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the Omvoh market going forward. Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from infections and harmful substances, mistakenly attacks healthy cells, tissues, or organs. The rise in autoimmune diseases is driven by factors such as genetic susceptibility, lifestyle influences, hormonal changes, and an aging population. Omvoh supports the management of autoimmune diseases by helping restore immune balance, neutralizing harmful antibodies, reducing inflammation, alleviating symptoms, and preventing further tissue damage. For instance, in July 2024, according to the National Health Service (NHS) England, a UK-based government department, multiple sclerosis affects more than 150,000 people in the UK, including over 120,000 individuals in England, and is more common among women. Around 135 new cases are diagnosed each week, underscoring the growing burden of autoimmune conditions. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the Omvoh market.

The increase in healthcare expenditure is expected to significantly drive the growth of the Omvoh market in the future. Healthcare expenditure refers to total spending on medical services, treatments, and healthcare infrastructure within a healthcare system or economy. Rising healthcare expenditure is fueled by aging populations, the growing prevalence of chronic diseases, advancements in medical technologies, and higher expectations for quality care. Increased healthcare spending supports greater investment in autoimmune disease management, improving access to therapies such as Omvoh that help regulate immune responses and enhance patient outcomes. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, rising healthcare expenditure is driving the growth of the Omvoh market.

Major companies operating in the Omvoh market are focusing on developing innovative solutions, such as advanced interleukin-23p19 (IL-23p19) antagonists, to address the growing demand for targeted autoimmune therapies that offer improved inflammation control and better long-term patient outcomes. IL-23p19 antagonists work by blocking the p19 subunit of the IL-23 cytokine, thereby reducing inflammatory signaling and providing a more selective and potentially better-tolerated treatment approach compared to broader immunosuppressive therapies. For instance, in December 2024, Eli Lilly and Company, a US-based pharmaceutical company, announced that Omvoh received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for approval in the European Union for treating adults with moderately to severely active Crohn’s disease. This recommendation was supported by results from the Phase 3 VIVID-1 trial, which demonstrated meaningful improvements in clinical and endoscopic outcomes compared with placebo and an active control.

Major companies operating in the omvoh market are Eli Lilly and Company.

North America was the largest region in the omvoh market in 2025. The regions covered in the omvoh market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the omvoh market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the Omvoh market by increasing costs of imported biologic manufacturing equipment, monoclonal antibody raw materials, injectable delivery systems, and cold-chain logistics services. Gastroenterology treatment centers in North America and Europe are most affected due to dependence on imported biologics infrastructure, while Asia-Pacific faces cost pressures in expanding biologic drug manufacturing. These tariffs are raising production and distribution costs for advanced therapies. However, they are also driving domestic biologics investment, regional manufacturing expansion, and greater resilience in inflammatory disease treatment supply chains.

The omvoh market research report is one of a series of new reports that provides omvoh market statistics, including omvoh industry global market size, regional shares, competitors with a omvoh market share, detailed omvoh market segments, market trends and opportunities, and any further data you may need to thrive in the omvoh industry. This omvoh market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Omvoh is a prescription medicine that contains the active ingredient mirikizumab-mrkz, a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a protein that plays a role in inflammatory pathways. It is indicated for the treatment of adults with moderately to severely active ulcerative colitis. The therapy generally starts with intravenous infusions during the induction phase, followed by subcutaneous injections as part of the maintenance regimen.

The main types of Omvoh formulations include tablets or capsules and injectable forms. Omvoh tablets or capsules provide a convenient oral option for managing chronic inflammatory conditions, supporting consistent dosing and ease of use. It is applied across multiple clinical indications, including ulcerative colitis (UC), Crohn’s disease, psoriasis, and others, and is used by a range of end users such as hospitals, clinics, pharmacies, and research institutions.

The omvoh market consists of sales of subcutaneous injections, intravenous infusion bags, and lyophilized powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.